|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-8-7
|
|
pubmed:abstractText |
We describe a novel syndrome of severe toxic symptoms during intravascular hemolysis due to impaired hemoglobin scavenging in 2 children with acute myeloid leukemia undergoing CD33-directed therapy with the immunotoxin gemtuzumab ozogamicin (GO). A simultaneous high plasma hemoglobin, haptoglobin, and low bilirubin after septicemia-induced intravascular hemolysis indicated abrogated clearance of haptoglobin-hemoglobin complexes. This was further supported by low levels of plasma soluble CD163 and a concordant low number of CD163-expressing monocytes. We show that CD163 positive monocytes and macrophages from liver, spleen, and bone marrow coexpress CD33, thus suggesting that the GO-induced cellular cytotoxicity of CD33 positive cells eradicates a significant part of the CD163 positive monocytes and macrophages. The risk of severe toxic symptoms from plasma hemoglobin should be considered after CD33-targeted chemotherapy when the disease is complicated by a pathologic intravascular hemolysis. Furthermore, the cases provide further circumstantial evidence of a key role of (CD163-expressing) monocytes/macrophages in plasma hemoglobin clearance in vivo.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Aminoglycosides,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, CD,
http://linkedlifedata.com/resource/pubmed/chemical/Antigens, Differentiation...,
http://linkedlifedata.com/resource/pubmed/chemical/CD163 antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Haptoglobins,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobins,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Scavenger,
http://linkedlifedata.com/resource/pubmed/chemical/gemtuzumab,
http://linkedlifedata.com/resource/pubmed/chemical/haptoglobin-hemoglobin complex
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1528-0020
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
15
|
|
pubmed:volume |
112
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1510-4
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18550848-Aminoglycosides,
pubmed-meshheading:18550848-Antibodies, Monoclonal,
pubmed-meshheading:18550848-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18550848-Antigens, CD,
pubmed-meshheading:18550848-Antigens, Differentiation, Myelomonocytic,
pubmed-meshheading:18550848-Drug Toxicity,
pubmed-meshheading:18550848-Female,
pubmed-meshheading:18550848-Haptoglobins,
pubmed-meshheading:18550848-Hemoglobins,
pubmed-meshheading:18550848-Hemolysis,
pubmed-meshheading:18550848-Humans,
pubmed-meshheading:18550848-Infant,
pubmed-meshheading:18550848-Leukemia, Myeloid, Acute,
pubmed-meshheading:18550848-Male,
pubmed-meshheading:18550848-Receptors, Cell Surface,
pubmed-meshheading:18550848-Receptors, Scavenger,
pubmed-meshheading:18550848-Syndrome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin.
|
|
pubmed:affiliation |
Department of Clinical Biochemistry, Arhus Sygehus, Aarhus University Hospital, Aarhus, Denmark.
|
|
pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|
